News

Aspyrian has received an exclusive license from the National Cancer Institute for a new ADC technology platform, Near-infrared Photoimmunotherapy (PIT), which is expected to offer highly efficient and

Pursuant to the terms of the agreement, AMRI will acquire all the outstanding shares of Cedarburg Pharmaceuticals for $38.2m in cash. The transaction, including $2.8m of assumed liabilities,

The FDA Division of Anesthesia and Analgesia Products agreed to a 505(b) regulatory pathway to obtain market approval for the product. The company anticipates initiating the pivotal pharmacokinetic

This new patent provides broader intellectual property rights relating to compositions and methods of developing and producing novel enzymes which efficiently convert different sources of plant biomass (for

IBM’s Big Data analytics technologies will be put to work on bacterial genetics and drug susceptibility tests to better understand the genomic mechanisms that cause resistance to antibiotics.

Mylan previously sued Teva alleging that Teva’s Abbreviated New Drug Application (ANDA) for this product infringed four Mylan patents covering Perforomist. After a full trial, the Court entered

The Australian and Philippine patents have been allowed with a very broad range of claims to a large number of families of chemical structure compositions, pharmaceutical compositions, methods

The company said that the new use is for people 12 years of age and older who remain symptomatic despite treatment with H1-antihistamine therapy. So far, H1-antihistamines have

Radiation proctitis (RP) is a significant unmet medical need, with no well-established standard of care. Access is actively seeking marketing partners globally for ProctiGard™. Access Pharmaceuticals president and